Antibodies that specifically bind to human IL-15 and uses thereof
US11267883B2 · kind B2 · utility
1Cited by
4References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 21, 2017 |
| Grant date | Mar 8, 2022 |
| Priority date | — |
| Expiry date | Dec 21, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/5443
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.